



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 5502**
Arpi MATOSSIAN-ROGERS : Attorney Docket No. 2003_1279
Serial No. 10/674,433 : Group Art Unit 1644
Filed October 1, 2003 : Examiner Amy E. Juedes, Ph.D.
LIGANDS, INCLUDING ANTIBODIES, : **Mail Stop: Amendment**
SHOWING REACTIVITY AGAINST
ENDOCRINE CELLS

RESPONSE TO RESTRICTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

Sir:

In response to the Restriction Requirement dated May 22, 2006, the period for response the having been extended for one month by the attached petition, Applicant herein provides the following remarks.

Applicant hereby elects with traverse the invention of Group XI, claim 30, drawn to a method of treating autoimmune disease with an antibody or fragment thereof which is capable of binding an anti-TCR V β antibody. Applicant further elects "organ-specific autoimmune disease" as the elected species for examination on the merits. It is respectfully submitted that the elected species reads on at least claim 30.

The Restriction and Election of Species Requirement are traversed on the grounds that all of the disease listed in the claims are linked by a common method of treatment. This is especially relevant in view of the central disease mechanism. As noted in the abstract of the PCT publication, the invention provides antibodies recognizing molecules on secretory cells of

various tissue targets of autoimmune disease, allowing a unified method of preventing and treating autoimmune diseases and other methods where hormonal dysregulation, hyperinsulinaemia and insulin resistance are involved.


Therefore, the methods directed to the different diseases do not differ with respect to ingredients and method steps. In this regard, the methods involve the same ingredients (i.e., same antibody) and the same method steps (administering an effective amount of the antibody).

Rejoinder of the non-elected species is respectfully requested upon allowance of the elected species.

Favorable action on the merits is solicited.

Respectfully submitted,

Arpi MATOSSIAN-ROGERS

By: 
Jay F. Williams
Registration No. 48,036
Attorney for Applicant

JFW/akl
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 18, 2006